Business
Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion
Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion.
About this update from Odyssey Health Inc.
[{"type":"text","content":"\n Irvine, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the \"Company\" or \"Odyssey\"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of their novel nano-particle drug formulation. The drug formulation was designed to enhance brain distribution of its lead drug candidate, PRV-002, to treat concussion (mild traumatic brain injury). “The combined nature of our new formulation and novel nasal device will maximize the exposure of the traumatized brain to our drug following concussion and give the best chance for effective treatment,” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International. “The novel nanoparticle drug formulation will improve safety by reducing exposure to areas of the body other than the intended treatment area, the brain,” The drug, a novel neurosteroid being developed to treat concussion, has been formulated into a nano-particle powder. The dried powder will now be pre-filled into Odyssey’s proprietary nasal device for clinical trials to begin this summer. The formulation is designed to improve the drug’s ability to cross the blood brain-barrier which should simultaneously provide the traumatized brain with support by reducing oxidative stress and inflammation. Delivering the drug directly to the brain will reduce systemic exposure of other organs and subsequent unwanted side effects. The combination of a nano-particle structure along with nasal dispersion stands to increase drug availability at traumatized areas of the brain. This targeted approach should reduce the amount of drug required per dose to get an efficacious response. “We are excited to team with Odyssey Group International to design this novel nano-particle formulation which can improve the crossing of their neuroprotective drug into the brain,” commented Clint Buchner, CEO of Envirostar, Inc. About Odyssey Group International, Inc.Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningfu...